AQUABOUNTY TECHNOLOGIES INC
Aquabounty Technologies Inc (AQB) is a micro‑cap biotechnology company that develops faster‑growing Atlantic salmon through its AquAdvantage genetic line. The commercial idea is to reduce time to market and production costs for farmed salmon, potentially improving the economics of aquaculture. With a market capitalisation around $6.28 million, AQB is small and highly speculative: shares can be volatile and liquidity is limited. The company has a notable regulatory history — including past FDA reviews — but commercial rollout has been slow and has faced operational, consumer‑acceptance and supply‑chain challenges. Potential upside exists if production scales, acceptance improves and sales grow, but risks include financing needs, regulatory changes, reputational concerns and operational setbacks. This information is educational only and not personal financial advice. Investors should carry out their own research, consider their risk tolerance and suitability, and be aware that values can rise or fall and returns are not guaranteed.
Stock Performance Snapshot
Analyst Rating
Analysts suggest selling Aquabounty Technologies stock as its target price is below its current value.
Financial Health
Aquabounty Technologies shows moderate financial performance with steady cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring AQB
Blue-Carbon & Ocean Health
Dive into a carefully selected group of stocks that are leading the blue economy revolution. These companies were hand-selected by our expert analysts for their innovative approaches to ocean sustainability, from advanced aquaculture to ecosystem restoration and marine technology.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growth Efficiency Case
AquAdvantage salmon aims to reach market size faster, which could lower unit costs if scaled; however, commercial adoption and economics remain uncertain.
Sustainable Aquaculture
Genetic improvements may support more efficient farming and reduced resource use, though consumer acceptance and regulation could limit market access.
Regulatory Watch
Past regulatory milestones matter for sales and exports; any future approvals or restrictions will materially affect prospects, and the small market cap adds risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
